For many adults, the most valuable blood work helps assess cardiovascular and metabolic risk: a standard lipid panel, glucose or hemoglobin A1c, and kidney function. Apolipoprotein B (ApoB) can sharpen the picture for selected individuals. Lipoprotein(a), or Lp(a), is worth checking at least once in adulthood under current cardiovascular guidance. Other tests belong in the clinical plan when symptoms, history, medications, or a specific risk profile justify them.
At Longevity Institute Miami, I start with the person in front of me: family medical history, resting blood pressure, current medications, sleep quality, physical activity, body composition, prior laboratory results, and personal health goals. That comprehensive clinical context determines which laboratory results are genuinely meaningful.
Start with the Tests That Can Change Care
1. A Standard Lipid Panel: The Essential First Look
A lipid panel measures total cholesterol, HDL cholesterol, triglycerides, and LDL cholesterol (usually calculated). It remains a foundation of cardiovascular prevention. LDL cholesterol reflects the cholesterol carried in LDL particles; triglycerides and non-HDL cholesterol add information about other circulating fats and cholesterol-carrying particles.
The panel becomes most useful alongside age, blood pressure, smoking status, diabetes, family history, and prior cardiovascular disease. A result may support a conversation about nutrition, exercise, medication, or additional risk assessment. Someone with known cardiovascular disease may need a very different treatment target from a healthy young adult. The 2026 ACC/AHA dyslipidemia guideline emphasizes assessing overall cardiovascular risk, including risk factors that a standard LDL number may miss.
2. ApoB: How Many Artery-Relevant Particles Are Circulating?
Think of LDL cholesterol as measuring some of the cargo carried by certain lipoproteins. Apolipoprotein B (ApoB) gives a closer estimate of the number of atherogenic particles because each relevant particle generally carries one ApoB molecule. These include LDL and several triglyceride-rich particles.
Why might the distinction matter? Two people can have similar LDL cholesterol but different ApoB results. In one person, many relatively cholesterol-poor particles may be circulating. This pattern can occur with elevated triglycerides, insulin resistance, type 2 diabetes, or metabolic syndrome.
ApoB is particularly helpful when standard lipid numbers and the rest of the clinical picture do not agree. It may also help assess whether treatment has lowered atherogenic particle burden. It does not replace the standard lipid panel or the physician’s assessment, and a single “optimal” value should not be applied to every patient. The 2026 ACC/AHA guideline includes ApoB among tools that may refine risk assessment in selected patients.
3. Lp(a): The Inherited Risk Factor Many People Have Never Measured
Lipoprotein(a), pronounced “L-P-little-a,” is a cholesterol-carrying particle whose circulating concentration is largely inherited. It is not included in a routine lipid panel. An elevated Lp(a) can increase the risk of atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis, even when other cholesterol results appear acceptable.
Current ACC/AHA guidance recommends measuring Lp(a) at least once in adulthood. It is especially informative when a parent or sibling developed cardiovascular disease early, or when a patient has familial hypercholesterolemia or unexplained early vascular disease.
Lp(a) may be reported in nmol/L or mg/dL. Those units cannot be converted with a single reliable formula for everyone, so interpret the value using the specific laboratory’s units and a clinician’s guidance. Because levels are usually genetically stable over life, most people do not need frequent repeat testing. Finding a high level prompts closer attention to LDL cholesterol, ApoB, blood pressure, smoking cessation, glucose, and family screening; it does not mean that an over-the-counter supplement can “cure” an inherited risk.
4. A1c & Fasting Glucose: Looking for Diabetes and Prediabetes
Hemoglobin A1c estimates average blood glucose exposure over approximately two to three months. According to the American Diabetes Association (ADA) diagnostic criteria:
- Normal Range: A1c below 5.7%
- Prediabetes Range: A1c between 5.7% and 6.4%
- Diabetes Threshold: A1c of 6.5% or higher (generally requiring confirmation when symptoms are absent)
Fasting plasma glucose is another established diagnostic test. These results matter because identifying prediabetes creates an early opportunity to address physical activity, nutrition, sleep, weight when appropriate, and metabolic health before microvascular damage occurs.
Clinical Caveat: A1c is not infallible. Anemia, altered red blood cell turnover, hemoglobinopathies, and advanced kidney disease can distort A1c readings. If the A1c does not fit the fasting glucose or clinical story, we investigate why before assigning a diagnosis or modifying therapy.
5. Do Not Overlook Kidney & Liver Health
A basic or comprehensive metabolic panel (BMP/CMP) includes serum creatinine and estimated glomerular filtration rate (eGFR), along with electrolytes and glucose. A comprehensive panel also measures liver enzymes (ALT, AST, ALP) and total bilirubin. These familiar baseline tests can uncover silent metabolic, biliary, or renal conditions that influence medication choices.
For individuals with hypertension, prediabetes, diabetes, or cardiovascular risk, a urine albumin-to-creatinine ratio (uACR) may reveal early microvascular kidney damage years before eGFR begins to fall. KDIGO’s 2024 Chronic Kidney Disease guideline utilizes both eGFR and albuminuria stages to stratify renal risk.
A Complete Blood Count (CBC) is also valuable when evaluating unexplained fatigue, suspected iron deficiency, immune status, or monitoring medication tolerance. Ordering it in context matters far more than marketing it as an “anti-aging panel.”
Which Additional Markers Deserve a Closer Look?
Beyond foundational cardiometabolic panels, targeted specialty markers can provide valuable clinical context when guided by symptoms, history, or specific risk factors:
High-Sensitivity CRP (hs-CRP)
hs-CRP can help refine cardiovascular risk assessment in selected patients. However, it is nonspecific: a common cold, dental infection, recent workout, or acute injury can elevate it. A single spike cannot diagnose chronic “inflammaging,” and care plans should never rely on this marker in isolation.
Fasting Insulin & HOMA-IR
Fasting insulin provides useful insight when a patient exhibits signs of insulin resistance despite normal fasting glucose. HOMA-IR is calculated from fasting glucose and insulin. Both require careful interpretation because commercial reference thresholds vary, and neither displaces A1c or formal diagnostic criteria.
Thyroid, Iron, B12 & Vitamin D
TSH investigates thyroid metabolism; ferritin and iron studies evaluate fatigue and storage capacity; Vitamin B12 is essential for patients on metformin, PPIs, or plant-based diets. For Vitamin D, the USPSTF notes there is insufficient evidence for indiscriminate screening in asymptomatic adults—testing should be guided by bone health, malabsorption, or clinical risk.
Targeted Hormone Panels
Hormone levels fluctuate with circadian timing, menstrual cycle phase, age, stress, and medications. Testosterone testing in men or perimenopause evaluations in women should always be paired with specific symptoms and proper timing—never ordered indiscriminately.
Tests That Deserve More Caution
Commercial “biological age” scores, unvalidated proprietary micronutrient panels, and exotic mitochondrial assays can produce colorful, multi-page reports without offering proven clinical pathways to improve patient outcomes.
Beware of Overtreatment from Arbitrary Flags
Commercial wellness tests should never crowd out established cardiovascular, oncologic, and metabolic prevention. Furthermore, treatment should never be initiated solely because a value falls slightly outside a private laboratory’s proprietary “optimal” bracket.
Likewise, repeating stable genetic markers like Lp(a) every few months adds unnecessary expense without clinical benefit. In contrast, repeating A1c, ApoB, lipid panels, or renal markers every 3 to 6 months makes clinical sense when tracking the objective response to a therapeutic or dietary intervention.
Dr. Gupta’s Approach to a Longevity Lab Review in Miami
At Longevity Institute Miami, we begin by reviewing any recent laboratory tests you have already completed so you do not pay to duplicate valid data. During an unhurried 60–90 minute consultation, Dr. Nina Gupta explores your personal medical background, family cardiovascular risk, physical performance, sleep architecture, and nutrition.
Together, we decide whether foundational testing answers your clinical questions or whether targeted panels—such as ApoB, Lp(a), uACR, or hormone profiling—will provide actionable insight.
The Broader Healthspan Picture:
Blood tests are only one piece of the healthspan puzzle. Resting blood pressure, cardiorespiratory fitness (VO₂ max), muscular strength, restorative sleep, and age-appropriate cancer screenings matter just as much to your longevity. A truly comprehensive longevity assessment creates space for all of them.